Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About

Trending Topics

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni

    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor & Employment
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations

    Industries

    View All

    • Cannabis
    • Consumer
    • Energy
    • Entertainment
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Non Profit
    • Real Estate
    • Technology

    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    1. Home
    2. People
    3. Ravinderjit Braich, Ph.D.People
    1. Home
    2. People
    3. Ravinderjit Braich, Ph.D.People

    Ravinderjit Braich, Ph.D.

    Partner


    • Boston
    • Office617.345.1089
    • rbraich@nixonpeabody.com
    • Download vCard
    • Share
    • LinkedIn Profile

    Introduction

    Dr. Ravi Braich has a chemistry background and is counsel in the Patent practice group. He focuses his practice on U.S. and foreign patent prosecution, opinion work, and counseling clients in the areas of chemicals, diagnostics, therapeutics, pharmaceuticals, biotechnology, and the life sciences.

    Practice Areas

    Intellectual PropertyLife Sciences

    My focus

    I focus my practice on helping clients, including hospitals, research institutes, and small and medium-sized companies, devise and pursue effective strategies for protecting their breakthrough technologies. I have experience in a wide range of technologies, including small molecules, nucleic acid-based technologies (RNAi, activating RNAs, antisense nucleic acids, and microRNAs), peptides, antibodies, prodrugs and drug conjugates, anesthetics, diagnostic/imaging agents, antiviral agents, cancer vaccines, semi-conductor materials, drug targeting and drug delivery, microfluidic devices, drug delivery devices, diagnostic devices, and biomimetic devices. This work involves their synthesis, purification, and use.

    Patent Prosecution

    I focus on strategic patent counseling and prosecution in the areas of chemicals, diagnostics, therapeutics, and pharmaceuticals in all phases of development, within and outside the United States.

    Patent Portfolio Management

    I work closely with corporations, universities, and licensee counsel on strategic management and growth of their patent portfolios.

    Opinion Work

    I work with clients in varieties of industries to conduct patentability and freedom to operate analysis and competitive intelligence and analysis in areas of small molecules, nucleic acids, polymers, and diagnostic methods and devices.

    European Union Unitary Patent (UP) and Unified Patent Court (UPC)

    I counsel clients on how the new European Union Unitary Patent and the opening of the Unified Patent Court (UPC) will affect all pending European applications and patents.

    Looking ahead

    Unless the Supreme Court reverses the “full scope” requirement, I expect to see more challenges to patents based on the written description/enablement requirements, not only in the chemical and biotechnology spaces but also in the high-tech space.

    Insights

    Selected publications

    • “More certainty on limits to early §101 challenges—How will this impact patent owners and applicants?” Intellectual Property & Technology Law Journal, May 2020 (co-author)
    • “A year out and a Supreme Court case still leaves patent questions unanswered,” Intellectual Property & Technology Law Journal, December 2019 (co-author)
    • “Some clarity to method of treatment claims from the Supreme Court?” Nixon Peabody Intellectual Property Alert, April 29, 2020
    • “Personalized treatment patenting in light of Vanda v. West-Ward,” Nixon Peabody Intellectual Property Alert, March 24, 2020
    • “Personalized therapy and subject matter eligibility,” Nixon Peabody Intellectual Property Alert, December 16, 2019

    Selected speaking engagements

    • “A brief introduction to IP for start-ups,” Starta Ventures, New York, August 2022
    • “Basics of intellectual property,” Starta Ventures, New York, March 2022
    • “Intellectual property rights,” Institute for Biomedical Entrepreneurship, Cambridge, Massachusetts, November 2021
    • “Patents, trademarks, and copyrights,” Starta Ventures, New York, September 2021
    • “IP considerations for start-ups,” Starta Ventures, New York, New York, September 2020
    • “I’m a start-up. What is intellectual property, and do I need it?” Starta Ventures, New York, May 2020
    • “Patentability of diagnosis and method of treatment claims in the US,” Harvard University, February 2020
    • “Patenting diagnosis and method of treatment claims in the US,” Children’s Medical Centre Corp., Boston, February 2020
    • “Why think about intellectual property for start-ups?” Starta Ventures, New York, September 2019
    • “Intellectual property—A brief primer,” The Indus Entrepreneurs (TiE) New York City Chapter, September 2019

    Representative experience

    • Provide a broad range of patent services, including patent portfolio management, to the following:
      •  A start-up company involved in cancer therapeutics and targeted drug delivery; work closely with the client in the strategic development of their IP portfolio
      • A pharmaceutical company involved in RNAi therapeutics; work closely with the client in the strategic development of their IP portfolio in core platform technologies related to RNAi
    • Helped develop the following:
      • A patent portfolio directed to new anesthetics for a large hospital-based research organization; work with the client and licensee to devise and execute strategies that extract the greatest value from the portfolio
      • Two separate patent portfolios directed in the diagnostic space for a large hospital-based research organization; work with the client and licensees to devise and execute strategies that extract the greatest value from the portfolio
    • Represented a company spun out of UCLA  developing novel oxysterol compositions for a range of clinical uses in patent prosecution and IP counseling

    Admitted to practice

    Massachusetts

    Education

    McGill University, Ph.D., Chemistry
    Suffolk University Law School, J.D., cum laude
    University of Toronto, B.Sc., Biochemistry

    Languages

    Punjabi

    In the News

    • Law360

      Nixon Peabody promotes eight attorneys to partner

      This article spotlights the 2023 new partner class, which includes Long Island Healthcare partner Jason Chimon; Boston Intellectual Property partner Ravi Braich; New York City Complex Disputes partner Alper Tosun; Affordable Housing & Real Estate partners Julia Casteleiro, Ari Glatt, and Kathie Soroka of New York and Ian O’Banion from San Francisco; and Washington, DC Community Development Finance partner Emily McKinney. The article also quotes CEO and Managing Partner Steve Zubiago.

      Feb 2, 2023
    • Bloomberg Law

      Wake Up Call

      This roundup of notable legal industry news and people moves includes Nixon Peabody’s promotion of 12 attorneys to counsel.
      Feb 17, 2021
    • Intellectual Property & Technology Law Journal

      More Certainty on Limits to Early Section 101 Challenges – How Will This Impact Patent Owners and Applications?

      Intellectual Property partner Pete Prommer in Chicago and associate Ravi Braich, Ph.D. in Boston contributed this article analyzing the Supreme Court’s denial of several petitions for certiorari on patent decision in HP Inc. v. Berkheimer, and the effect on patent owners and applicants. Click here for the full article.
      May 2, 2020
    • Intellectual Property & Technology Law Journal

      A Year Out and a Supreme Court Case Still Leaves Patent Questions Unanswered

      Intellectual Property associates Sydney Pritchett, Ben Rosborough and Ravi Braich authored this patent alert about remaining questions and uncertainty following the U.S. Supreme Court ‘s ruling in Helsinn Healthcare S.A. v. Teva Pharmaceuticals U.S.
      Dec 5, 2019

    Insights And Happenings

    View All
    • Alert

      Updated—European Patent System: What’s different for 2023?

      Sep 13, 2022
    • Alert

      Some clarity to method of treatment claims from the Supreme Court?

      April 29, 2020
    • Alert

      Personalized treatment patenting in light of Vanda v. West-Ward

      March 24, 2020
    View All

    Professionals in the Practice Area

    View All
    • Seth D. Levy

      Partner / Leader, Intellectual Property Practice / Co-chair, Life Sciences Practice
      • Los Angeles
      • Office:213.629.6161
      • slevy@nixonpeabody.com
      Seth D. Levy
    • Jennette W. Psihoules

      Counsel
      • Washington DC
      • Office:202.585.8385
      • jpsihoules@nixonpeabody.com
      Jennette W. Psihoules
    • Janet M. Garetto

      Partner
      • Chicago
      • Office:312.425.8514
      • jgaretto@nixonpeabody.com
      Janet M. Garetto
    • Andrew Y. Choung

      Partner
      • Los Angeles
      • Office:213.629.6166
      • achoung@nixonpeabody.com
      Andrew  Y. Choung
    • Jennifer Hayes

      Partner
      • Los Angeles
      • Office:213.629.6179
      • jenhayes@nixonpeabody.com
      Jennifer Hayes
    View All

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • © 2023 Nixon Peabody. All rights reserved
    • Privacy Policy
    • Terms of Use
    • Statement of Client Rights
    • Supplier Diversity Program
    • Nixon Peabody International LLC
    • PAL